Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 390

1.

FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.

Lv B, Ma L, Tang W, Huang P, Yang B, Wang L, Chen S, Gao Q, Zhang S, Xia J.

Cell Physiol Biochem. 2018 Jul 12;48(1):158-172. doi: 10.1159/000491715. [Epub ahead of print]

PMID:
30001540
2.

Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin.

Chae H, Cho H, Yoo C, Kim KP, Jeong JH, Chang HM, Kang J, Lee HC, Lim YS, Kim KM, Shim JH, Lee SS, Park DH, Song TJ, Hwang S, Song GW, Moon DB, Lee YJ, Lee JH, Ryoo BY.

Int J Biol Markers. 2018 Jun 1:1724600818777239. doi: 10.1177/1724600818777239. [Epub ahead of print]

PMID:
29874985
3.

Nutritional prognostic scores in patients with hilar cholangiocarcinoma treated by percutaneous transhepatic biliary stenting combined with 125I seed intracavitary irradiation: A retrospective observational study.

Cui P, Pang Q, Wang Y, Qian Z, Hu X, Wang W, Li Z, Zhou L, Man Z, Yang S, Jin H, Liu H.

Medicine (Baltimore). 2018 Jun;97(22):e11000. doi: 10.1097/MD.0000000000011000.

4.

Differential diagnostic roles of the serum CA19-9, total bilirubin (TBIL) and the ratio of CA19-9 to TBIL for benign and malignant.

Liu W, Liu Q, Wang W, Wang P, Chen J, Hong T, Zhang N, Li B, Qu Q, He X.

J Cancer. 2018 Apr 19;9(10):1804-1812. doi: 10.7150/jca.25093. eCollection 2018.

5.

Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size.

Ni T, Shang XS, Wang WT, Hu XX, Zeng MS, Rao SX.

Br J Radiol. 2018 Jun 5:20180017. doi: 10.1259/bjr.20180017. [Epub ahead of print]

PMID:
29791202
6.

An undifferentiated carcinoma at Klatskin-position with long-term complete remission after chemotherapy.

Köhler BC, Goeppert B, Waldburger N, Schlamp K, Sauer P, Jäger D, Weiss KH, Macher-Göppinger S, Schulze-Bergkamen H, Schirmacher P, Springfeld C.

Oncotarget. 2018 Apr 24;9(31):22230-22235. doi: 10.18632/oncotarget.25125. eCollection 2018 Apr 24.

7.

[A Case of Metastasis of Cholangiocarcinoma to the Bladder].

Okumura A, Morii A, Takagawa K, Kitamura H.

Hinyokika Kiyo. 2018 Apr;64(4):165-168. doi: 10.14989/ActaUrolJap_64_4_165. Japanese.

PMID:
29772618
8.

Detection of early-stage extrahepatic cholangiocarcinoma in patients with biliary strictures by soluble B7-H4 in the bile.

Ke W, Zeng L, Hu Y, Chen S, Tian M, Hu Q.

Am J Cancer Res. 2018 Apr 1;8(4):699-707. eCollection 2018.

9.

A novel nomogram for the prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis complicated by imagiologically diagnosed mass.

Chen G, Yu H, Wang Y, Li C, Zhou M, Yu Z, Zheng X, Wu X, Shan Y, Zhang Q, Zeng Q.

Cancer Manag Res. 2018 Apr 23;10:847-856. doi: 10.2147/CMAR.S157506. eCollection 2018.

10.

Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis.

Cuenco J, Wehnert N, Blyuss O, Kazarian A, Whitwell HJ, Menon U, Dawnay A, Manns MP, Pereira SP, Timms JF.

Oncotarget. 2018 Apr 3;9(25):17430-17442. doi: 10.18632/oncotarget.24732. eCollection 2018 Apr 3.

11.

Prognostic biomarkers for cholangiocarcinoma and their clinical implications.

Saengboonmee C, Sawanyawisuth K, Chamgramol Y, Wongkham S.

Expert Rev Anticancer Ther. 2018 Jun;18(6):579-592. doi: 10.1080/14737140.2018.1467760. Epub 2018 Apr 26.

PMID:
29676221
12.

Preoperative criterion identifying a low-risk group for lymph node metastasis in intrahepatic cholangiocarcinoma.

Yoh T, Hatano E, Seo S, Terajima H, Uchida Y, Taura K, Yasuchika K, Uemoto S.

J Hepatobiliary Pancreat Sci. 2018 Jun;25(6):299-307. doi: 10.1002/jhbp.552. Epub 2018 May 22.

PMID:
29656560
13.

Relationship between blood parameters and Clonorchis sinensis infection: A retrospective single center study.

Chen H, Chen S, Huang Z, Kong L, Hu Z, Qin S, Qin X, Li S.

Int Immunopharmacol. 2018 Jun;59:120-126. doi: 10.1016/j.intimp.2018.04.003. Epub 2018 Apr 10.

PMID:
29653409
14.

[CA19-9 in intrahepatic cholangiocarcinoma : A diagnostic and prognostic armamentarium?]

Juntermanns B, Kaiser GM, Itani Gutierrez S, Heuer M, Buechter M, Kahraman A, Reis H, Kasper S, Paul A, Fingas CD.

Chirurg. 2018 Jun;89(6):466-471. doi: 10.1007/s00104-018-0636-z. German.

PMID:
29644426
15.

Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.

Tshering G, Dorji PW, Chaijaroenkul W, Na-Bangchang K.

Am J Trop Med Hyg. 2018 Jun;98(6):1788-1797. doi: 10.4269/ajtmh.17-0879. Epub 2018 Apr 5.

PMID:
29637880
16.

Surgical Indication for Advanced Intrahepatic Cholangiocarcinoma According to the Optimal Preoperative Carbohydrate Antigen 19-9 Cutoff Value.

Yamamoto Y, Sugiura T, Todaka A, Okamura Y, Ito T, Ashida R, Kakuda Y, Nakanuma Y, Uesaka K.

World J Surg. 2018 Apr 4. doi: 10.1007/s00268-018-4605-y. [Epub ahead of print]

PMID:
29619514
17.

The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma.

Qiu Y, He J, Chen X, Huang P, Hu K, Yan H.

Clin Chim Acta. 2018 May;480:186-192. doi: 10.1016/j.cca.2018.02.008. Epub 2018 Feb 10.

PMID:
29438681
18.

Impact of serum carbohydrate antigen 19-9 level on prognosis and prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma.

Yamada T, Nakanishi Y, Okamura K, Tsuchikawa T, Nakamura T, Noji T, Asano T, Tanaka K, Kurashima Y, Ebihara Y, Murakami S, Shichinohe T, Mitsuhashi T, Hirano S.

J Gastroenterol Hepatol. 2018 Feb 10. doi: 10.1111/jgh.14124. [Epub ahead of print]

PMID:
29427472
19.

[A Case of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern].

Sekiya M, Sakamoto K, Matsukuma S, Tokuhisa Y, Tokumitsu Y, Matsui H, Kanekiyo S, Tomochika S, Iida M, Takeda S, Suzuki N, Yoshino S, Hazama S, Hoshii Y, Nagano H.

Gan To Kagaku Ryoho. 2017 Nov;44(12):1877-1879. Japanese.

PMID:
29394806
20.

Extended left hepatectomy for intrahepatic cholangiocarcinoma: hepatic vein reconstruction with in-situ hypothermic perfusion and extracorporeal membrane oxygenation.

Balci D, Ozcelik M, Kirimker EO, Cetinkaya A, Ustuner E, Cakici M, Inan B, Alanoglu Z, Bilgic S, Akar AR.

BMC Surg. 2018 Jan 31;18(1):7. doi: 10.1186/s12893-018-0342-2.

Supplemental Content

Loading ...
Support Center